Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Beyond Air's Debt-to-EBITDA or its related term are showing as below:
FRA:48L'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.86 Med: -0.25 Max: 0
Current: -0.86
FRA:48L's Debt-to-EBITDA is ranked worse than 100% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs FRA:48L: -0.86
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Beyond Air Debt-to-EBITDA Related Terms
Beyond Air Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Beyond Air's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:48L vs POAS, RMSL, LUDG: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Beyond Air's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Beyond Air's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Beyond Air (FRA:48L) has a Debt-to-EBITDA of -0.71 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Beyond Air. According to the industry distribution chart, Beyond Air ranks #999999 out of 472 companies in the Medical Devices & Instruments industry.
Is Beyond Air's Debt-to-EBITDA too high?
Beyond Air's current Debt-to-EBITDA is -0.71. Based on the distribution chart, Beyond Air ranks #999999 out of 472 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Beyond Air has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's Debt-to-EBITDA compare to POAS and RMSL?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #999999 out of 472 companies for Debt-to-EBITDA. This places Beyond Air in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Beyond Air. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beyond Air's current Debt-to-EBITDA is -0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Beyond Air (FRA:48L) has a current Debt-to-EBITDA of -0.71. The stock's GF Value™ is €1,700.68, compared to a current price of €65.60 — trading 96.1% below its estimated fair value. The current Debt-to-EBITDA is -0.71. Beyond Air's overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Beyond Air (FRA:48L), the current Debt-to-EBITDA is -0.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beyond Air (FRA:48L) Overvalued in 2026?
Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued.
The current stock price of €65.60 is trading 96.1% below its estimated GF Value™ of €1,700.68.
Key valuation signals for FRA:48L:
Debt-to-EBITDA: -0.71
GF Value™: €1,700.68 vs. price of €65.60 (96.1% below fair value)
No single metric tells the full story. See the FRA:48L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
25GF Score
Get the complete analysis for FRA:48L
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:48L has been successfully added to your 
